ライフサイエンスコーパス: nontransplant

1 d higher than reported in the literature for nontransplants.

2 (1.3+/-0.5 vs. 2.0+/-0.7 mg/dL, P=0.01) than nontransplanted amyloid patients.

3 idence is also available from studies in the nontransplant and relapsed settings.

4 Normal (nontransplanted) and diabetic Lewis rats transplanted wi

5 Nontransplanted animals served as control.

6 s in the transplanted group as compared with nontransplanted animals.

7 rase chain reaction (qPCR) were performed on nontransplanted aortas and grafts explanted 2 and 4 week

8 Nontransplant approaches for treating aCML have otherwis

9 Similar recordings were performed in nontransplant areas of the transplant-recipient eyes, an

10 : 10.8 +/-12.0 spikes/1.6 sec) compared with nontransplant areas of these recipient eyes (mean: 2.4 +

11 mice transplanted with B6 marrow or control nontransplanted B6-E mice.

12 upporting their role as permanent therapy in nontransplant candidates are limited.

13 f frontline treatment in both transplant and nontransplant candidates.

14 the operating room, death determination by a nontransplant caregiver, and rapid aortic cannulation, l

15 crease risk for poor health outcomes in many nontransplant chronic disease populations, lung recipien

16 fter KT, compared with a large population of nontransplanted CKD patients and with low-risk control p

17 transplantation are comparable with those of nontransplanted CKD patients with similar levels of kidn

18 To provide the nontransplant clinician with a basic understanding of th

19 tality was higher in the transplant than the nontransplant cohort (relative risk [RR], 5.85; P < .000

20 The nontransplant cohort included 196 patients receiving hyd

21 antly younger than the average age of 70 for nontransplanted control patients with renal neoplasms.

22 aris and M mulatta) were used as a diabetic, nontransplanted control.

23 smatched renal transplant recipients and 101 nontransplant controls in a four-stage study including m

24 After 10 years, 137 survivors and nontransplant controls, case-matched on age, sex, and ra

25 rences of gait parameters when compared with nontransplanted controls (P<0.05).

26 eased immunostaining for C5b-9 compared with nontransplanted controls, confirming local complement ac

27 there was virtually no remyelination in the nontransplanted controls.

28 rs were significantly elevated compared with nontransplanted controls.

29 ients, 7 liver transplant recipients, and 10 nontransplanted controls.

30 nsplanted with normal islets or nondiabetic, nontransplanted controls.

31 cebo-controlled study of 260 nonneutropenic, nontransplanted, critically ill patients with ICU-acquir

32 NI (KT-CNI-SCC) or mTOR-i (KT-mTORi-SCC), 25 nontransplants developing SCC (NoKT-SCC) and 6 healthy c

33 als of the allografts were compared with the nontransplanted donor aorta.

34 The INTrEPID (Investigation of Nontransplant-Eligible Patients Who Are Inotrope Depende

35 here were six ascertained mortalities in the nontransplant group and one death in the transplanted gr

36 days after islet infusion, compared with the nontransplanted group (P = 0.005 and <0.001, respectivel

37 tients with AT >/=40%, with one death in the nontransplanted group and no deaths in the transplanted

38 ation as well as total pancreatectomy alone (nontransplanted group).

39 atients and 26 months (range, 0.1-37) in the nontransplanted group.

40 del.' The observed actuarial survival in the nontransplanted groups was much better than anticipated

41 h a gene expression database obtained for 55 nontransplant HCV-infected and uninfected liver samples.

42 line compared with AS-treated allografts and nontransplanted heart controls.

43 ty gene expression arrays, and compared with nontransplanted hearts using the log-average ration (LAR

44 vBcl-2-treated hearts were no different from nontransplanted hearts.

45 Nontransplanted hemophilia A mice died within a few hour

46 vely similar to those previously observed in nontransplanted, immunized solid-tumor patients.

47 s (atorvastatin and dasatinib), approved for nontransplant indications, could regulate specific CRM g

48 transcript levels in urine specimens from 41 nontransplant individuals, 11 with UTI and 30 without UT

49 76 through 2014, and 10 age- and sex-matched nontransplanted individuals for each of the groups from

50 Germany, Switzerland, and Japan, as well as nontransplant isolates from both human immunodeficiency

51 g depicts early adaptations in the remaining nontransplanted kidney of donors after nephrectomy.

52 ADCT values in nontransplanted kidney of donors increased from a preexp

53 b-C9), can cause acute pulmonary distress in nontransplanted lungs.

54 igher inflammatory responses in DCs than did nontransplanted lysates, suggesting DC-mediated response

55 It is often measured in nontransplant medical and surgical conditions but has on

56 allograft recipients, and it is observed in nontransplanted mice and after CD8 T cell depletion with

57 Nontransplanted mice and stromal-vascular fraction sampl

58 In septic, nontransplanted mice at 24 hours, Ppara mice had elevate

59 Separate groups of nontransplanted mice underwent cecal ligation and punctu

60 tests (compared with those of 7 nontreated, nontransplanted mice with streptozotocin-induced diabete

61 alloreactive T cells were similar to naive, nontransplanted mice.

62 th after allogenic SCT vs those treated with nontransplant modalities was 5.6 (95% CI, 1.7-19; P = .0

63 hemistry were similar among transplanted and nontransplanted MSUD patients.

64 compared with EBV (-) transplant (n=15), and nontransplant (n=13) livers.

65 ransfer of mature allogeneic NK cells in the nontransplant or transplant setting has been shown to be

66 HCV specimens compared with a few controls (nontransplant: P <.001; transplant: P =.001) and contras

67 contrasted to the weak staining of controls (nontransplant: P <.001; transplant: P =.001).

68 etected in HCV cases compared with controls (nontransplant: P <.001; transplant: P =.006), which corr

69 to the absent to weak staining of controls (nontransplant: P =.001; transplant: P =.009).

70 The acini of normal, nontransplanted, pancreas, control specimen were consist

71 hat of their 823 matched dialysis waitlisted nontransplanted partners (91.6%, 74.5%, and 55.5% vs. 88

72 isease caused by a Trichosporon species in a nontransplant patient with cystic fibrosis.

73 ars to be similar to what is observed in the nontransplant patient.

74 ednisone) metabolism was determined in eight nontransplant patients and in transplant recipients rece

75 Obesity in nontransplant patients has been associated with hyperten

76 y) was investigated in nearly 900 successive nontransplant patients undergoing coronary angiography.

77 In nontransplant patients with chronic hepatitis C virus (H

78 Furthermore, although twin studies in nontransplant patients with NMSC suggest a low genetic c

79 as strains causing sporadic cases of PCP in nontransplant patients with or without HIV infection.

80 ial stages of the disease process, which, in nontransplant patients, occurs long before clinical pres

81 with an increased incidence of cirrhosis in nontransplant patients, the authors tested the hypothesi

82 nding the natural history of this disease in nontransplant patients, this does not hold true for the

83 mily is associated with altered NMSC risk in nontransplant patients, we examined allelism in GSTM1, G

84 ic load of HCV genomes between the post- and nontransplant patients, whereas serum titers in the form

85 ors behaving more aggressively than those in nontransplant patients.

86 tabolism, and accelerated atherosclerosis in nontransplant patients.

87 d between non-lung transplant recipients and nontransplant patients.

88 ased for transplant recipients compared with nontransplant patients.

89 d die following a severe sepsis episode than nontransplant patients.

90 factor for coronary artery disease (CAD) in nontransplant patients.

91 significantly better survival compared with nontransplanted patients (17 deaths) (hazard ratio, 4.48

92 ical neoplasms were identified in 32/1325 of nontransplanted patients and 15/701 transplanted patient

93 Among nontransplanted patients at these centers, 2206 patients

94 rol group consisted of hospital autopsies on nontransplanted patients from the odd-numbered years, 19

95 portional hazards regression analysis of our nontransplanted patients identified serum bilirubin, ser

96 The observed actuarial survival of nontransplanted patients was compared with the expected

97 e of 7 years (age range, 1.5-18.2 years) and nontransplanted patients with juvenile MLD born between

98 rospective observational study, we recruited nontransplanted patients with P-CID aged 1 to 16 years t

99 did not receive transplantation (hereafter, nontransplanted patients) with juvenile MLD.

100 Among the nontransplanted patients, 5-year survival after disease

101 ostic Scoring System (IPSS-R), developed for nontransplanted patients, also correlates with post-HCT

102 mproving the cardiovascular risk profiles of nontransplanted patients, but the health benefits and po

103 In the nontransplanted patients, HBeAg was initially detectable

104 15 (21%) and 6 (20%) of the transplanted and nontransplanted patients, respectively.

105 Compared with the nontransplanted patients, the transplanted patients were

106 Unlike sinus node dysfunction in nontransplanted patients, which typically worsens with t

107 and lower MRI severity scores compared with nontransplanted patients.

108 the sickest critically ill, nonneutropenic, nontransplanted patients.

109 In the nontransplant pediatric population, adenovirus infection

110 d outcome of bronchiolitis obliterans in the nontransplant, pediatric population.

111 Nontransplant physicians need education about donor risk

112 with cytomegalovirus (CMV) infection in the nontransplant population and evidence of CMV infection i

113 same cutoffs for defining proteinuria in the nontransplant population are applied.

114 Compared with a matched nontransplant population, the incidence ratios for MI an

115 d intrinsic acute kidney injury (AKI) in the nontransplant population.

116 were also predictors of restenosis as in the nontransplant population.

117 ort data from large cohort studies in normal nontransplant populations, which suggested a higher risk

118 idney transplantation and how it compares to nontransplant populations.

119 proteins measured were higher than in normal nontransplant populations.

120 er cardiovascular morbidity and mortality in nontransplant populations.

121 etes, cardiovascular morbidity, and death in nontransplanted populations, which may help us to unders

122 In the nontransplanted primates given the same immunosuppressio

123 raphic and histologic findings that occur in nontransplant PSC patients.

124 8 +/- 7.9 mumol/L vs 17.5 +/- 5.1 mumol/L in nontransplant Rag mice, P < 0.05).

125 esponses were never recorded in age-matched, nontransplanted RCS rats.

126 pients who developed NSCLC had worse OS than nontransplant recipients due to competing risks of death

127 All nonneutropenic, nontransplant recipients managed in five intensive care

128 studies with CNIs, and the usage of CNIs in nontransplant recipients.

129 fracture incidence in recipients compared to nontransplant reference groups matched on age, sex, and

130 detected in the plasma of lung transplant or nontransplant sepsis patients.

131 lished as standard of therapy for MDS in the nontransplant setting, the role of these agents in patie

132 tumor-free survival than vaccination in the nontransplant setting.

133 ve of response to antiviral treatment in the nontransplant setting.

134 reducing leukemia burden before HSCT and in nontransplant settings requires further studies.

135 areful evaluation of the available effective nontransplant strategies.

136 A large number of nontransplant studies have, however, reported an associa

137 re than 10 years of follow-up and 94 healthy nontransplanted subjects as controls.

138 To evaluate the efficacy of nontransplant surgery for pediatric cholestasis, 58 clin

139 This was a multicenter analysis of nontransplant surgical approaches to intrahepatic choles

140 Nontransplant surgical interventions are important adjun

141 SRSB is a nontransplant surgical option for patients with SBS who

142 ner with an understanding of the spectrum of nontransplant surgical options for managing patients wit

143 nts with a diagnosis of cirrhosis undergoing nontransplant surgical procedures between January 1, 199

144 after chemotherapy through aggressive use of nontransplant surgical procedures.

145 ality for patients with cirrhosis undergoing nontransplant surgical procedures.

146 ant regardless of the model used to estimate nontransplant survival.

147 In cohort A (nontransplant), SVR12 was achieved by 86%-89% of patient

148 sease status, donor selection, and effective nontransplant therapies.

149 une diversification following transplant and nontransplant therapies.

150 vival may result from earlier, low-intensity nontransplant therapy, and aggressive pursuit of reduced

151 Patients at low risk should receive nontransplant therapy, whereas individual counseling is

152 en, including both liver transplantation and nontransplant treatment options.

153 are to discuss standard and investigational nontransplant treatment strategies for acute myeloid leu

154 likely to respond, at least transiently, to nontransplant treatment.

155 ons of QOL outcomes after BMT or alternative nontransplant treatments are appearing in the literature

156 (K) transplanted type-1 diabetics (n=5), and nontransplanted type-1 diabetics (n=12) served as contro

157 Compared with a cohort of post-OLT and nontransplanted viremic HCV patients, the index patient